Wanbury Limited (BOM:524212)
267.15
-7.35 (-2.68%)
At close: Jun 15, 2026
Wanbury Revenue
In the fiscal year ending March 31, 2026, Wanbury had annual revenue of 6.50B INR with 8.35% growth. Wanbury had revenue of 1.65B in the quarter ending March 31, 2026, a decrease of -4.68%.
Revenue
6.50B
Revenue Growth
+8.35%
P/S Ratio
1.43
Revenue / Employee
4.71M
Employees
1,382
Market Cap
9.32B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 6.50B | 500.89M | 8.35% |
| Mar 31, 2025 | 6.00B | 224.42M | 3.88% |
| Mar 31, 2024 | 5.78B | 780.91M | 15.63% |
| Mar 31, 2023 | 5.00B | -115.39M | -2.26% |
| Mar 31, 2022 | 5.11B | 1.19B | 30.23% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| TTK Healthcare | 8.57B |
| Anuh Pharma | 7.72B |
| Lincoln Pharmaceuticals | 7.04B |
| Sudarshan Pharma Industries | 7.03B |
| Kopran | 6.81B |
| Fredun Pharmaceuticals | 6.35B |
| Fermenta Biotech | 5.25B |
| Syncom Formulations (India) | 4.89B |
Wanbury News
- 6 days ago - Wanbury successfully clears TGA inspection at Tanuku API facility - Business Upturn
- 4 months ago - Wanbury begins commercial production of high-potent anaesthetic API - Business Upturn
- 9 months ago - Wanbury implements SAP S/4HANA ERP to drive future ready operations - Business Upturn
- 1 year ago - Wanbury launches next-gen iron supplement ‘C RED’ to revolutionize anemia management in India - Business Upturn
- 1 year ago - Wanbury receives GMP certification from ANVISA for Patalganga facility - Business Upturn
- 1 year ago - Wanbury’s Tanuku facility in Andhra Pradesh completes ANVISA inspection with zero observations - Business Upturn
- 1 year ago - Wanbury launches Wanbury C-RED and Ketamine Hydrochloride - Business Upturn
- 1 year ago - Wanbury shares rise 2.56% following company refinances Rs 95 crore NCDs, reducing interest costs - Business Upturn